Adaptin Bio, Inc.

What they do

Adaptin Bio, Inc. is a biotechnology company focused on developing product candidates for inflammatory and autoimmune diseases. Its operations are centered on a patent license agreement with Duke University, along with a sponsored research agreement, to advance its preclinical and clinical programs. The company has no marketed products and its activities are primarily research and development, with a small administrative infrastructure.

Revenue drivers

• No commercial products — The company has no approved or marketed products, so it currently generates no product revenue.
• Licensing and collaboration — Potential future revenue could arise from its license agreement with Duke University, but no payments are currently recognized.
• Equity financing — The company's primary cash inflows come from equity offerings and other financing activities, not operations.

Recent performance

For the fiscal year ended December 31, 2025, Adaptin Bio reported a net loss of $5.2 million and used $4.8 million in operating cash, compared to a net loss of $3.1 million and $649,283 operating cash used in 2024. Diluted EPS worsened from $-0.96 in 2024 to $-0.66 in 2025. As of June 30, 2026, the company had $670,488 in cash, total assets of $981,452, and total liabilities of $2.6 million, resulting in a shareholder deficit of $1.7 million.

Strategy

The company plans to continue developing its product candidates, relying on its licensed intellectual property from Duke University and a sponsored research agreement. It aims to advance candidates through preclinical studies and into clinical trials, with the goal of obtaining FDA approval. The company also seeks to raise additional capital to fund operations, as indicated by its going concern discussion and recent equity subscription agreements.

Risks

• Going concern risk — The company may not have sufficient cash to fund operations for the next twelve months, as indicated by its cash position and ongoing losses.
• Dependence on third-party IP — The company depends on maintaining its license rights to intellectual property from Duke University; loss of these rights would impair its ability to develop products.
• Regulatory approval risk — The company's product candidates are in early development and require FDA approval, which is uncertain and may not be obtained.
• Limited operating history — As a recently merged shell company, the company has limited operating history and has not generated revenue, which may affect its ability to scale.

Outlook

Management expects to continue incurring substantial losses as it advances its development pipeline. The company plans to secure additional funding through equity offerings and other financing to support its operations. It is focused on progressing its lead candidates toward clinical milestones, but acknowledges the need for ongoing capital and successful execution of its development plan.